Protalix BioTherapeutics Q2 Earnings Call: Robust Growth Amid Challenges

Protalix BioTherapeutics reported a 50% increase in revenue from H1 2025 compared to the same period last year, driven by Elfabrio sales. The company anticipates Elfabrio royalties to exceed $100 million by 2030 and plans to initiate a Phase II study for PRX-115 in H2 2025. Despite regional challenges and rising expenses, the overall sentiment remains positive due to strong partnerships and market potential.

Protalix BioTherapeutics (PLX), a commercial-stage biotech company, has reported a 50% increase in revenue from H1 2025 compared to the same period last year. The growth was primarily driven by the sales of Elfabrio, an enzyme replacement therapy for Fabry disease [1].

Elfabrio is positioned in a lucrative global market, estimated at USD 2.3 billion in 2025, with expectations to reach USD 3.2 billion by 2030. Protalix anticipates that royalties from Elfabrio could exceed $100 million by 2030, reflecting its potential to capture a significant market share [2].

The company's partnership with Chiesi has been a cornerstone of its operational strategy, with Chiesi making substantial investments in medical, regulatory, and commercialization programs for Elfabrio. This collaboration is expected to drive further growth and market penetration [2].

Protalix also reported a significant turnaround in its financial performance. The company achieved a net income of approximately $164,000 for Q2 2025, marking a 16% increase compared to Q2 2024. However, the company faced regional challenges, with a decrease in sales to Brazil and Pfizer, attributed to timing differences [2].

The development of PRX-115, a promising gout product candidate, is progressing well. Protalix plans to initiate a Phase II study in the second half of 2025, building on encouraging results from previous studies [2].

Despite facing some challenges, the overall sentiment remains positive due to strong partnerships and market potential. Protalix anticipates Elfabrio royalties to exceed $100 million by 2030, based on a projected 15% to 20% market share of the $3.2 billion Fabry disease market [2].

References:

[1] https://seekingalpha.com/article/4816436-protalix-speculative-buy-promising-plant-cell-platform-elfabrio-ramp?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=ee9ec53fb31c4b5c98ba2f38e48bbc6b

[2] https://www.tipranks.com/news/company-announcements/protalix-biotherapeutics-reports-robust-growth-amid-challenges